Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemolizumab for prurigo nodularis (Phase 2, Germany)
2017-001715-36Phase 2Completed
- Sponsor
- Galderma
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prurigo nodularis (PN) comparing Nemolizumab with Placebo (2 arms). Primary endpoint: Percent change in weekly average of peak pruritus NRS. Started Jul 2017; status: completed.
02
Drugs
nemolizumab
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on 2017-001715-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001715-36.